• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

1.61 EUR+1.00 %31.7. klo 18.29
5,675 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.00 %
-8.93 %
-25.71 %
-59.09 %
-57.24 %
-63.07 %
-49.63 %
-90.60 %
-64.80 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
34.58M EUR
Turnover
24.14K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
07.05.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
LinkedIn AI Diabetic Eye Exams: How One Clinic Closed the Care Gap | AEYE Health "We finally have a solution for our retinopathy screening. It is the easiest system that we have worked with." Making a real difference in closing care gaps comes down to one thing: workflow fit. Adding...
7/30/2026, 2:43 PM
39
New research publication from AEYE Health, pretty decent results: Autonomous AI-Driven Point-of-Care Screening for Diabetic Retinopathy Compared to Reading Center Multi-Expert Clinical Review: Results from Three Prospective Controlled Pivotal Validation Studies with AEYE-DS in Over...
7/29/2026, 5:53 AM
by Sheikki
33
Redeye has updated its views on Optomed. The full article is available with a subscription. Optomed: Portable Cameras and AI Reshaping Eye Screening 2026-07-28 Optomed trades below Redeye’s Fair Value estimate of EUR 3.45 per share, has a Market Edge score of 5 for Value (Cheap) ...
7/29/2026, 6:43 AM
by Sheikki
29
Excellent reference for the Aurora Aeye solution. It seems the tedious pilots, validations, audits, and other back-and-forth have been completed, and we can now publicly announce—through a clearly satisfied customer reference—that the thing works. There are likely more of these cases...
yesterday
by Sheikki
28
As I understand it, this bolsters the portable device’s capabilities/suitability and alleviates concerns regarding desktop devices. The study highlights that over 99% of the images taken were suitable for AI without pupil-dilating drops (non-mydriatic). Furthermore, inter-device ...
7/29/2026, 9:25 AM
by Pekka
23
A cost-comparison study based on a small sample in Canada; AI-based screening for diabetic retinopathy is half the cost of a human-performed diagnosis. The study used DRSPlus and Eyenuk’s Eyeart. BMJ Open Ophthalmology Screening for diabetic retinopathy with artificial intelligence...
yesterday
by Sheikki
21
Is it any wonder it’s falling? Due to a weak first quarter, confidence in the goal of “revenue growth” is being tested. We still haven’t heard anything official from Big Pharma. They’re probably ordering reporting consulting and planning at a “devilish” price, and even then, it will...
7/24/2026, 7:13 AM
by Kulukurssi
20
Read more on our forum
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8.
2026

Interim report Q2'26

6.11.
2026

Interim report Q3'26

Press release23.06.2026 klo 10.43

Redeye: Optomed: Solid device order

Optomed
Regulatory press release18.06.2026 klo 17.30

Inside Information: Optomed receives a large order in the US

Optomed
Press release11.05.2026 klo 16.16

Redeye: Optomed (Q1 Interview): Expecting normalised sales in upcoming quarters

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release08.05.2026 klo 20.00

Optomed Oyj: Decisions of the Organization Meeting of Optomed's Board of Directors

Optomed
Regulatory press release08.05.2026 klo 14.30

Optomed Oyj: Decisions of the Annual General Meeting

Optomed
Press release08.05.2026 klo 11.10

Redeye: Optomed (Q1 Review): Soft sales weigh on sentiment

Optomed
Press release06.05.2026 klo 11.51

Redeye: Optomed (Q1 Initial take): Softer quarter than expected

Optomed
Regulatory press release06.05.2026 klo 09.00

Optomed Oyj: Optomed Plc: Interim report January - March 2026

Optomed
Regulatory press release09.04.2026 klo 13.00

Optomed Oyj: Notice Of The Annual General Meeting Of Optomed Plc

Optomed
US market roadmap for medical devices – a European perspective
Analyst Comment27.03.2026 klo 12.45 by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release27.02.2026 klo 09.00

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed
Regulatory press release25.02.2026 klo 09.00

Optomed Oyj: Optomed Annual Report 2025 published

Optomed
Press release11.02.2026 klo 14.31

Redeye: Optomed Q4 (Review): Devices segment supports outlook despite cautious guidance

Optomed
Press release10.02.2026 klo 14.16

Redeye: Optomed Q4 (Initial take): Sales in line; EBIT impacted by a one-off cost

Optomed
Regulatory press release10.02.2026 klo 09.00

Optomed Oyj: Optomed Plc: Financial Statements Bulletin January - December 2025

Optomed
Regulatory press release29.01.2026 klo 13.30

Optomed Oyj: Proposal of Optomed's Nomination Board

Optomed
Press release21.01.2026 klo 11.00

Optomed Oyj: Optomed Achieves ISO 27001 Certification for Information Security Management Systems

Optomed
Press release12.01.2026 klo 09.00

Optomed Oyj: Optomed and Aireen Announce Strategic Partnership and Achieve Approval for AI-Powered Handheld Diabetic Retinopathy Screening

Optomed
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video16.12.2025 klo 09.30

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Regulatory press release12.12.2025 klo 15.45

Optomed Oyj: New shares subscribed for in Optomed Plc's directed share issue have been registered in the Finnish Trade Register

Optomed